Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 15/20 | 0.58 |
| ▸ | PDE4A | P27815 | 12/20 | 0.58 |
| ▸ | HTR3A | P46098 | 2/20 | 0.42 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7173742 | 0.92 | KCNH2 (0.57) | KCNH2PDE4AIKBKETBK1 | |
| SCHEMBL7175610 | 0.84 | KCNH2 (0.61) | KCNH2PDE4A | |
| SCHEMBL7169656 | 0.84 | KCNH2 (0.62) | KCNH2PDE4A | |
| SCHEMBL7966418 | 0.82 | PKM (0.44) | KCNH2PDE4AIKBKETBK1 | |
| SCHEMBL7167976 | 0.82 | PDE4A (0.59) | KCNH2PDE4A | |
| SCHEMBL7175570 | 0.81 | PDE4A (0.60) | KCNH2PDE4A | |
| SCHEMBL7170288 | 0.81 | KCNH2 (0.59) | KCNH2PDE4AHTR3A | |
| SCHEMBL7176811 | 0.81 | PDE4A (0.67) | KCNH2PDE4A | |
| SCHEMBL7167073 | 0.80 | KCNH2 (0.86) | KCNH2PDE4A | |
| SCHEMBL7169736 | 0.80 | PDE4A (0.64) | KCNH2PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552205-B1 | Antileukemia and antitumor agents | FLORIDA STATE UNIVERSITY | 2003-04-22 | — | — | US | disclosed |
| US-6541480-B2 | Controlling cytokines | SUNTORY LIMITED (JP) | 2003-04-01 | — | — | US | disclosed |
| US-6462208-B2 | ANTITUMOR AGENTS | FLORIDA STATE UNIVERSITY | 2002-10-08 | — | — | US | disclosed |
| US-20020006935-A1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2002-01-17 | — | — | US | disclosed |
| US-20020002292-A1 | Antitumor agents | HOLTON ROBERT A (US) | 2002-01-03 | — | — | US | disclosed |
| US-6297248-B1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | SUNTORY LIMITED (JP) | 2001-10-02 | — | — | US | disclosed |
| US-5998656-A | ANTICANCER, ANTITUMOR AGENTS; LEUKEMIA | FLORIDA STATE UNIVERSITY (US) | 1999-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002292-A1 | Antitumor agents | TP53, MCL1, TOP2A | KCNH2 4646/4885PDE4A 2935/4885HTR3A 3367/4885 |
| US-20020006935-A1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | PDE3A, PDE5A, PDE3B | KCNH2 559/4885PDE4A 4/4885HTR3A 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.